Washington, DC, May 23, 2011 --(PR.com
)-- YES! Beat Liver Tumors, a nonprofit organization dedicated to the support of patients diagnosed with primary or metastatic liver tumors, hosed an event in collaboration with George Washington University Hospital (GWU) on Wednesday, May 18. YES! advocates worked with liver cancer specialists from GWU to raise awareness for liver tumor treatment options in the greater Washington, D.C. area.
“Every year more than 250,000 Americans are with liver tumors and like myself, many are told to get their affairs in order,” said Suzanne Lindley, co-founder and executive director of YES! and 10-year colon cancer survivor. “We wanted to let patients and physicians know there are treatment options available – it is no longer a death sentence.”
The Liver Seminar series, taking place at medical centers across the country, is designed to provide patients and caregivers the opportunity to hear Lindley’s empowering story that there is hope despite the devastating diagnosis. Joining Suzanne were GWU physicians Dr. Showkat Bashir who discussed prevention and surveillance of liver cancers, Dr. Paul Lin who lectured on surgical options for both primary and metastatic liver tumors, Dr. Harvey I. Katzen who spoke about chemotherapeutic management of cancers of the liver, Dr. Shawn Sarin who shared emerging therapies that are offered, such as transarterial chemoembolization, radiofrequency ablation, and Selective Internal Radiation Therapy (SIRT) using Yttrium-90 microspheres, that directly target liver tumors while sparing healthy liver tissue. Each of the physicians conveyed the importance of a multidisciplinary approach to treatment. Afterwards, patients had the opportunity to ask questions of this elite team and also time to interact with one another.
“This event provided patients in our area a great opportunity to hear Suzanne’s inspirational survival story and learn more about their treatment options,” said Dr. Sarin. “At GWU we are utilizing some of the latest therapies available to treat liver cancer, and we are excited to share this information with patients and the community.”